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Abstract 
Background: In the postgenomic era, it has become evident that analysis of genetic and protein expression changes 
alone is not sufficient to understand most disease processes in e.g. cardiovascular and cancer disease. Biobanking has 
been identified as an important area for development and discovery of better diagnostic tools and new treatment 
modalities. Biobanks are developed in order to integrate the collection of clinical samples from both healthy individu‑
als and patients and provide valuable information that will make possible improved patient care. Modern healthcare 
developments are intimately linked to information based on studies of patient samples from biobank archives in large 
scale studies. Today biobanks form important national, as well as international, networks that share and combine 
global resources.
Methods: We have developed and validated a novel biobanking workflow process that utilizes 384‑tube systems 
with a high speed sample array robot with unique processing principles.
Results: The 384‑tube format and robotic processing is incorporated into a cancer and cardiovascular diagnostic/
prognostic research program with therapeutic interventions. Our biobank practice has gained acceptance within 
many hospitals and research units and is based on high‑density sample storage with small aliquot sample volumes. 
The previous standard of 5–10 mL sample volume tubes is being replaced by smaller volumes of 50–70 μL blood frac‑
tions that typically result in hundreds of thousands of aliquot fractions in 384‑tube systems.
Conclusions: Our novel biobanking workflow process is robust and well suited for clinical studies.
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Background
Patient and society’s demand and expectations in health 
care combined with rising costs pose a great challenge 
on our health care system. The scientific community is 
expected to develop solutions that can improve clinical 
outcome and increase cost efficiency without jeopardiz-
ing the quality of care of individual patients. Future health 
care will be tailored to the individual and the introduc-
tion of personalized medicine in routine healthcare relies 
heavily on large scale biorepositories, biobanks (http://
www.informatics-review.com/wiki/index.php/Biobank-
ing_Definition) [1, 2].
Millions of clinical samples are collected every day 
for use in diagnostic tests that support clinical decision 
making. The majority of clinical routine samples are 
discarded but it is estimated that over one billion clini-
cal samples are stored in biobanks worldwide [3]. The 
preservation of these samples is an important undertak-
ing since each sample is unique and has the potential to 
facilitate future research and diagnostics.
Most errors in a hospital laboratory are due to preana-
lytical factors, if the preanalytical procedure fails sub-
sequent downstream measurements will also fail [4, 5]. 
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Preanalytical errors still account for 60-70% of all mis-
takes in laboratory diagnostics and in nearly one-fifth of 
these, errors might be associated with further inappro-
priate investigations and unjustifiable increase in costs 
[6].
The stability of a biospecimen sample depends on 
the method of storage. The vials must be sealed tightly, 
stored at the right temperature and the issue of possible 
freeze/thaw damage studied [7]. In almost all biobanks 
the samples are stored in 96-tube systems and each tube 
regularly used on more than one occasion. The current 
methods of sample handling and storage are often differ-
ent in different laboratories, a fact that further compli-
cates inter-laboratory studies, e.g. clinical multi-center 
studies.
Personalized medicine will be based on different diag-
nostic technologies used for studies of e.g. the human 
proteome. Results from proteome studies approaches [8–
11] are important complements to genomic data [11–15] 
and provide crucial information about the target driver 
molecules and their post-translational modifications.
Quantitative mass spectrometry is an excellent way 
to identify biomarkers that can be used in personalized 
medicine. The technology is very sensitive and thus the 
sample quality is of utmost importance. We believe that 
new strategies must be advanced and established for the 
integration and use of biobank samples in routine health 
care, samples from patients that can be collected, pro-
cessed and stored by a large scale archiving strategy.
We have previously reported on automated processing 
with robotic liquid handling for blood sample standardi-
zation developments for large scale biobanking [16, 17], 
as well as developments within standardized biobank 
workflows with evidence of sample history, tracking 
information, ensuring the sample integrity [18].
We hereby present a semi-automated workflow for 
biobank samples utilizing the high density 384-tube sys-
tem where the rigidity and performance of the automated 
platform is used within cancer and cardiovascular studies 
outlined in Fig. 1.
Methods
Liquid chromatography mass spectrometry
The peptide separation was carried out using a Thermo 
UPLC system (EASY nLC 1000, Thermo Scientific, San 
José, CA, USA). Aliquots of 0.5–1 µg of digested samples 
were injected onto a trap column (Acclaim PepMap100, 
C18, 5  µm, 100  Å, 300  µm i.d. ×5  mm, PN 160454, 
Thermo Scientific, San José, CA, USA). Peptides were 
then separated on an analytical column (Acclaim Pep-
Map RSLC C18, 2 µm, 100 Å, 75 µm i.d. ×25 cm, nanoVi-
per column, PN 164536, Thermo Scientific, San José, 
CA, USA) using a solvent gradient (0–40% acetonitrile 
in 90  min). Peptides separated on nanoLC system were 
analyzed with Q Exactive mass spectrometer is a positive 
ion mode. Samples were analyzed using an spray voltage 
and heated capillary temperature of 1.75 kV and 280°C, 
respectively. Data was acquired in a top ten data depend-
ent acquisition mode (DDA), in which a high resolu-
tion 70,000 (at m/z 200)MS survey scan (m/z 350–1800, 
AGC value of 1e6, maximum injection time of 100  ms) 
was followed by an acquisition of tandem mass spectra 
(35,000 (at m/z 200), target AGC value of 1e6, maxi-
mum injection time of 120 ms). For the ten most intense 
ions, HCD fragmentation was performed and the MS/
MS spectra were acquired. Dynamic exclusion was set to 
20 s. The proteotypic peptides for each protein as well as 
the best transitions for each peptide are summarized in 
supplement.
Sample array robot
The Sample Array Tube Handler (Thermo Scientific, San 
José, CA, USA) is specifically designed to be used with 
384-tube plates. The platform is designed to hold up to 
20 plates and can operate at lower temperatures (−20°C).
Tubes can be automatically transferred from a source 
plate (A) to a target plate (B) using two columns Excel 
file containing lists of tubes with source and destination 
positions. There are no requirements where to place the 
racks, all of the positions are open for both source and 
target plates.
The test was performed under three different 
conditions:
  • At room temperature.
  • At 5–8°C (cold room).
  • At −20°C (freezer).
A large number of movements were made during the 
test period of the Sample Array robot.
We used several different picking profiles to check 
robot performance under all three conditions. When 
running the Sample Array robot in a freezer a web cam-
era was installed together with a web interface to control 
the robot from outside.
Results and discussion
Preserving the integrity of clinical samples
Biobank sample integrity is paramount for subsequent 
studies but also other factors are important for showing 
the community that we are acting responsibly. Today’s 
clinical scientist needs to be prepared to not only collect 
and validate their raw gene-and protein- data and to safe 
keep the stored samples, but also to establish and main-
tain a legal administration for documenting the position 
of every individual sample in the biobank by a process 
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that de-identifies the actual personal information linked 
to a specific sample. Currently the sample processing of 
blood samples from patients is performed at short cycle 
times within hospitals, typically 2  h [12–15]. The 2  h 
include the collection from the patient, sample handling, 
centrifugations, and aliquoting into 384 tube racks, i.e., 
from the time the needle goes into the arm until the ali-
quoted blood fractions are stored at −80°C. The work-
flow of the semi-automated 384-tube system processing 
and storage is depicted in Fig. 1. The protocol is used in 
cancer- and cardiovascular studies. In this workflow sys-
tem, each 384 rack will hold one or two patients, depend-
ing on the number of primary tubes collected in the 
study. Here we typically use five primary tubes (6  mL) 
with blood containing various anticoagulants (EDTA, 
citrate, heparin). All blood fractions end up in the same 
rack due to the lack of time to distribute the aliquots into 
multiple 384-racks. This is the price that has to be paid, 
in order to manage handling blood samples from patients 
in a time cycle of less than 2 h.
Prior to protein expression analysis, the process-
ing protocols are similar for both tissues from resected 
tumors from cancer patients, and blood samples from 
cardiovascular patients, as shown in Fig. 2. We have pro-
cessed several series of sample cohorts in the sample 
work up protocols as outlined with high reproducibility 
and adaptability [10–12, 14].
Proteomics analysis of biobank samples are currently 
performed in a large number of studies where the out-
put with the latest high-resolution mass spectrometers is 
approx 100–150,000 protein sequences for a given tumor 
tissue sample and approx. 10–15,000 protein sequences 
analysed in blood fractions such as plasma or serum. Two 
examples are provided where protein sequence expres-
sions are presented for two patients (see Fig. 3).
Most of the peptides are eluted during a cycle time of 
40  min, if dead volumes are corrected for (30–70  min. 
These high resolution nano-chromatograms show 
extreme power, where the interface to the mass spec-
trometer is carrying out the second part of the separation 
along with the peptide annotation (nano LC–MS), fol-
lowed by the peptide sequencing (nano LC–MS/MS).
This biobank workflow is currently utilized at the center 
of excellence in biological and medical mass spectrome-
try “CEBMMS” at Lund University in Sweden (http://ceb-
mms.lu.se). The center is an investigator initiated activity 
with members in the Faculties of Medicine, Science, and 
Engineering, performing a number of clinical studies in 
















Fig. 1 Biobanking work flow in the hospital where automated processing of 384‑tube systems are processed by the “384 Sample Array Robot”.
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Automated processing of 384 sample tubes
Patient samples from the hospital were retrieved as out-
lined in Fig. 1, with the configured workflow steps being 
documented by barcode tagging. Frozen tissue sample 
processing was carried out as described in Fig. 2, where 
the solid tissue sections are homogenized, ending up as 
tissue extract solution samples. By this procedure, we are 
Fig. 2 Protocol used for the sample preparation of clinical patient samples within biobank studies, using both tumor tissue and blood fractions.
Fig 3 Resulting nano‑chromatographic separation of biobank samples.
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able to efficiently handle both biofluids and solubilized 
tissue extracts in the Sample Array Tube Handler system.
Automated sample processing is the only way to man-
age large sample numbers in sample archives where 
sample integrity is ensured [15, 16]. The increase in the 
number of high quality biobank samples results in an 
increased demand for the most appropriate sample type 
from a given sample set for proteomics and/or genomic 
studies. Large sample collections also need detailed clini-
cal records matched that are matched to the sample being 
readily available.
Correspondingly, in order for us to maintain the sam-
ple integrity and quality over time in large scale biobank-
ing, we apply the principle of single usage [17]. Single 
usage means, by our definition, that for any given stored 
sample in a biobank archive, it will be thawed once and 
never re-entered into the biobank for further storage. 
By this principle, we will ensure that sample integrity of 
each and every biofluid fraction or tissue is not variably 
changed by repeated thawing and freezing cycles. This 
consideration is especially relevant to large cohort stud-
ies where samples can easily reach thousands in number, 
thus we need controlled, efficient and automated work-
flows [18, 19]. The capacity of biobank sample collections 
is directly related to parallel automated processing. We 
are employing automated liquid handling instrumenta-
tions (HAMILTON robot MicroLab Starlet, Hamilton, 
Bonaduz AG, Switzerland) and high-density storage at 
−80°C (LICONIC freezer STT1k5 ULT, Liconic AG, 
Mauren, Liechtenstein). Currently, our ultralow robotic 
temperature storage facilities (−80°C), is able to store 
samples from clinical studies at a density of 5 million 
tubes using the 384-tube format, within a single freezer 
unit of approximately 3 m3 in volume.
In order to investigate the rigidity and stability of the 
Sample Array Tube Handler, we performed repeated 
picking and sorting steps in the 384 rack system. This was 
performed in an experimental setting using 4 different 
384-racks filled with 384 separate sample tubes that were 
transferred over the platform board, from one end to the 
other.
The processing steps were performed according to the 
following protocol. A sample transfer scheme with spe-
cific XY positions was created in a method part of the 
Sample Array software. Tubes from the series of source 
plates (A) were then transferred to the destination series 
of plates (B) according to the designed scheme.
1. Open method part of the S384 software.
2. Design of the sample transfer with specific XY posi-
tions.
3. Pick up the sample tube from the A series of racks.
4. Deliver the sample tube from the A series of racks to 
the B series of racks.
Each step within the method is monitored and a cor-
responding CSV file is generated. An example of the 
data output file generated after transfer is presented in 
Table 1, where the X–Y coordinate of each sample tube 
transfered from A1, B1, C1 and D1 to the A2, B2, C2 and 
D2-384-tube plates are tracked.
The entire operation of 4 × 384 tubes is experimentally 
1 cycle within our evaluation and validation of the S384 
platform, integrated into a biobank environment. We 
have performed more than 100,000 single tube transfers 
on the platform with the protocol described above. The 
platform allows transfer of tubes from 10 source plates 
into 10 destination plates.
Each transfer step takes about 4.5  s, which results in 
a total experimental time of close to 13 h non-stop pro-
cessing for transfer of 10,000 tubes.
We have performed sample transfer experiments, both 
within a day, in-between days and in-between weeks. In 
total we have processed more than 100,000 transfers over 
a 1 month period. We had no failures reported through-
out these experiments over a 1  month period.The data 
was generated at ambient temperature. We also repeated 
the same experiments at −20°C and found the rigidity of 
the Sample Array platform to be very similar to that of 
the ambient performance. The resulting report file gener-
ated from each cycle with 10,000 sample tubes indicated 
no errors. Five cycles were studied.
The sample quality is maintained throughout the 
biobank handling processes which is illustrated in the 
resulting proteomics spectra shown in Fig.  3 where 
patient tissues were analysed by LC–MS using a Q 
Exactive platform.
Sample tube distribution into multiple racks by scrambling
Large scale biobanks with millions of sample tubes need 
a given structure and organization in order to ensure the 
safety of the samples. In principle the sample archive 
should have a backup. In this respect, all sample tubes 
from a single patient should never be stored within one 
384 rack. Instead, the sample tubes should be divided 
and spread into multiple plates. In addition, a backup of 
each sample collection, approx 10–20% should be stored 
physically in another center located elsewhere, in order 
to make sure that the samples will never be lost.
Scrambling of samples into multiple racks can easily be 
achieved with the Sample Array Tube Handler platform.
Biobank space optimization and refilling the 384 racks
With multiple studies going on at the same time the sam-
ple flow in and out of the biobank is highly active. The 





































































































































































































































































































































































































































































































































































































































































































































































































Page 7 of 8Malm et al. Clin Trans Med  (2015) 4:27 
samples in a biobank will shift over time as samples are 
being collected and exported to research groups, in addi-
tion to the steady growth of the number of samples. 
These dynamic events will require that sample storage 
capacity is optimised.
Upon sample retrievals from biobanks, sample tubes 
from different 384-racks will be partly empty. In addition, 
the constant patient recruitment with tens of thousands 
of sample tubes per month makes it necessary to re-fill 
the 384-racks. The 384 robotic platform is an efficient 
work horse to fulfil this imoportant task.
384‑sample tube tightness
The tightness of the tube sealing, when processed with 
the robotic fine mechanics arm, was investigated with 
tubes containing blood samples in liquid form (23°C) as 
well as with frozen blood (−20°C), and solubilized tissue 
extracts. The blood fractions from cancer and cardio-
vascular patient samples were processed as described in 
Fig. 1. The sample tubes were investigated by microscope 
in order to look for any deterioration in the alumina film 
that covers the 384 tubes. A sample set of 1,000 tubes 
was investigated at ambient temperature, and we could 
not see any traces of harm or deterioration on these tube 
coatings. Resistance to leakages was also investigated. 
The 84 racks were placed in a swing out centrifuge and 
centrifuged for 10  min. Upon reinvestigation we exam-
ined the racks for any leakages caused by the centrifuga-
tion. None of the sample tubes containing plasma and 
erythrocyte blood fractions showed any trace of leakage, 
which was considered a confirmation of the excellent 
performance of the Sample Array Tube Handler.
Laboratory information management system (LIMS)
The data handling process workflow of our biobank 
infrastructure is outlined in Fig. 4, where the 384 robotic 
processing plays a central role in the overall handling of 
patient samples. Consequently, the CSV-file generated by 
the Sample Array Tube Handler platform for each of 384 
plates is automatically fed into the database through the 
laboratory information management system (LIMS). The 
new positions of each and every tube are aligned within 
the given study in the LIMS. The 2D barcode makes it 
possible to track each tube and position within the 384 
rack. The clinical data that is associated with the sample 
tube of each patient is also linked to the CSV-file from 
the robot.
Workflow advantages
The issue of poor biospecimen quality has often not 
been discovered until large number of clinical assays 
were performed or study reports already released [20]. 
The present system generates 70 µL aliquotes of whole 
blood (EDTA), plasma (EDTA, heparin, citrate), buffy 
coat (EDTA, heparin, citrate), red blood cells (EDTA, 
heparin, citrate) and serum in a 384-tube format using a 
fully automated sample processing strategy. This highly 
standardized procedure minimizes the probability of pre-
analytical errors and also makes possible the use of high 
quality samples on every occasion by avoiding the use of 
previously thawed samples.
The biobank practice can be implemented in clini-
cal routine in hospital laboratories and has now gained 
acceptance within several health care units. Instead of 
larger 5–10 mL tubes or the 96-tube format the current 
system typically gives the biobank user access to hun-
dreds of thousands of high quality small sample aliquots.
Concluding remarks
The impact of personalized medicine with targeted treat-
ments is increasing and it is not surprising that develop-
ing personalized medicine methodologies now conquer 
much of the current development portfolio within big 
pharma and the biotech industry. Translating basic sci-
ence to discover novel and improved treatments is a 
huge challenge [21, 22]. Automated picking and sorting 
of samples in biobanks and sample repositories is a stra-
tegically important part of modern healthcare operations 
in order to advance our understanding and knowledge 
of the molecular and environmental basis of human dis-
eases. The ultimate healthcare goal that forms the basis 
of large recent investments in biobanks is to provide the 
prerequisites for refined and improved diagnostics and 
treatments. This will eventually aid in developing per-

















Fig 4 Schematic illustration of our work flow with electronic surveil‑
lance and LIMS integrated system.
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